---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-270275"
form_type: "8-K"
ticker: "LXEO"
cik: "0001907108"
company_name: "Lexeo Therapeutics, Inc."
filed_at: "2026-06-15T11:05:59+00:00"
generated_at: "2026-06-15T11:10:36.108019+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Lexeo finalizes SUNRISE-FA 2 pivotal trial for LX2006 in FA cardiomyopathy; BLA submission expected H1 2028

## Summary
- Open-label pivotal trial of LX2006: 13 treated vs 13 untreated control; primary endpoint LVMI at 6 months.
- BLA submission under accelerated approval on track for H1 2028; topline data readout expected H2 2027.
- FDA removed co-primary endpoint of cardiac frataxin protein expression; trial powered for LVMI effect size ≥15%.
- Pediatric cohorts included; untreated control participants eligible to cross over to LX2006 after 6 months.
- CLARITY-FA natural history study ongoing, shares inclusion criteria; first patient enrollment by end of June 2026.

## SEC filing metadata
- accession: 0001193125-26-270275
- form_type: 8-K
- ticker: LXEO
- cik: 0001907108
- company_name: Lexeo Therapeutics, Inc.
- filed_at: 2026-06-15T11:05:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1907108/000119312526270275/0001193125-26-270275-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1907108/000119312526270275/lxeo-20260615.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-270275
- JSON: https://secwatch.observer/filing/0001193125-26-270275.json
- Plain text: https://secwatch.observer/filing/0001193125-26-270275.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.